$-1.09 EPS Expected for Blueprint Medicines (BPMC); Lakeland Bancorp Has 1.19 Sentiment

April 19, 2018 - By Adrian Mccoy

Lakeland Bancorp, Inc. (NASDAQ:LBAI) Logo

Lakeland Bancorp Inc (LBAI) investors sentiment decreased to 1.19 in Q4 2017. It’s down -0.26, from 1.45 in 2017Q3. The ratio worsened, as 43 hedge funds increased or started new stock positions, while 36 decreased and sold stakes in Lakeland Bancorp Inc. The hedge funds in our database now own: 25.22 million shares, up from 24.73 million shares in 2017Q3. Also, the number of hedge funds holding Lakeland Bancorp Inc in top ten stock positions was flat from 1 to 1 for the same number . Sold All: 7 Reduced: 29 Increased: 33 New Position: 10.

Analysts expect Blueprint Medicines Corporation (NASDAQ:BPMC) to report $-1.09 EPS on May, 2.They anticipate $0.25 EPS change or 29.76% from last quarter’s $-0.84 EPS. After having $-1.23 EPS previously, Blueprint Medicines Corporation’s analysts see -11.38% EPS growth. The stock decreased 1.61% or $1.42 during the last trading session, reaching $86.77. About 272,603 shares traded. Blueprint Medicines Corporation (NASDAQ:BPMC) has risen 101.73% since April 19, 2017 and is uptrending. It has outperformed by 90.18% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 4 selling transactions for $1.33 million activity.

Mcrae Capital Management Inc holds 2.47% of its portfolio in Lakeland Bancorp, Inc. for 304,653 shares. Cardinal Capital Management Llc Ct owns 1.99 million shares or 1.51% of their US portfolio. Moreover, Banc Funds Co Llc has 1.33% invested in the company for 1.48 million shares. The New York-based Mendon Capital Advisors Corp has invested 0.92% in the stock. Systematic Financial Management Lp, a New Jersey-based fund reported 970,345 shares.

The stock decreased 0.25% or $0.05 during the last trading session, reaching $19.7. About 154,923 shares traded or 36.87% up from the average. Lakeland Bancorp, Inc. (LBAI) has risen 3.96% since April 19, 2017 and is uptrending. It has underperformed by 7.59% the S&P500.

Lakeland Bancorp, Inc. operates as the holding firm for Lakeland Bank that provides financial services and products for individuals and small to medium sized businesses. The company has market cap of $934.88 million. It offers commercial banking depository products, including savings, money market, and time accounts, as well as demand deposits; lending solutions, such as short and medium term loans, lines of credit, letters of credit, inventory and accounts receivable financing, real estate construction loans, mortgage loans, small business administration loans, commercial real estate loans, commercial and industrial loans, and equipment financing solutions, as well as merchant credit card services; and wire transfer, Internet banking, mobile banking, night depository, and cash management services. It has a 18.07 P/E ratio. The firm also provides consumer banking services, including checking accounts, savings accounts, NOW accounts, money market accounts, certificates of deposit, secured and unsecured loans, consumer installment loans, mortgage loans, and safe deposit services.

Analysts await Lakeland Bancorp, Inc. (NASDAQ:LBAI) to report earnings on April, 26. They expect $0.33 earnings per share, up 26.92% or $0.07 from last year’s $0.26 per share. LBAI’s profit will be $15.66M for 14.92 P/E if the $0.33 EPS becomes a reality. After $0.29 actual earnings per share reported by Lakeland Bancorp, Inc. for the previous quarter, Wall Street now forecasts 13.79% EPS growth.

Among 10 analysts covering Blueprint Medicine Corp (NASDAQ:BPMC), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Blueprint Medicine Corp had 26 analyst reports since February 22, 2016 according to SRatingsIntel. The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) has “Buy” rating given on Wednesday, September 20 by Canaccord Genuity. The rating was initiated by BTIG Research on Friday, September 29 with “Buy”. The firm earned “Buy” rating on Monday, November 6 by Wedbush. The firm earned “Buy” rating on Wednesday, August 2 by Cowen & Co. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. BTIG Research maintained the shares of BPMC in report on Tuesday, October 31 with “Buy” rating. Canaccord Genuity maintained Blueprint Medicines Corporation (NASDAQ:BPMC) rating on Wednesday, August 2. Canaccord Genuity has “Buy” rating and $5600 target. JMP Securities maintained Blueprint Medicines Corporation (NASDAQ:BPMC) on Monday, April 16 with “Buy” rating. The stock of Blueprint Medicines Corporation (NASDAQ:BPMC) earned “Buy” rating by Cowen & Co on Tuesday, June 6. Jefferies maintained the shares of BPMC in report on Friday, December 22 with “Buy” rating.

Lakeland Bancorp, Inc. (NASDAQ:LBAI) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts